Infection with human immunodeficiency virus (HIV) can result in immunosuppression, allowing opportunistic pathogens to cause disease. Certain opportunistic infections are associated with increases in viral load, which may accelerate HIV progression or increase transmission of HIV. [1, 2, 3] Opportunistic infections are a major cause of morbidity and mortality in HIV-infected patients; however, with the availability of antiretroviral therapy, there is a decline in the incidence of opportunistic infections in both low- and high-income countries.
Treatment of Hepatitis B Virus With Coexisting HIV Infection
Patients with HIV infection are at a greater risk for hepatitis B virus (HBV) infection, due to the common route of transmission.
Patients with HIV infection are at a higher risk for developing cirrhosis, hepatic decompensation, and hepatocellular carcinoma than patients diagnosed with only chronic HBV infection. [6, 7]
Treatment of HIV infection may improve the virological, histological, and clinical evolution of chronic HBV infection. 
Several antiretroviral agents, such as emtricitabine, lamivudine, and tenofovir, have activity against HIV and HBV, while others, such as entecavir, have limited activity against HIV but lead to the development of HIV-resistant strains if used alone. 
Prior to the initiation of antiretroviral therapy, all patients who test positive for hepatitis B surface antigen (HBsAg) should be tested for HBV deoxyribonucleic acid (DNA) using a quantitative assay to determine the level of HBV replication. 
Chronic HBV is defined as testing positive for HBsAg for more than 6 months  ; patients with chronic HBV infection already receiving antiretroviral therapy active against HBV should undergo quantitative HBV DNA testing every 6-12 months. 
Routine screening and immunization are recommended for all HIV-infected patients to prevent primary HBV infection; however, the immune response to HBV vaccine is lower in patients with HIV infection than in uninfected patients, and postvaccination HBsAg must be tested to document immunity. [11, 12, 13, 14]
All patients with HBV/HIV coinfection must be assessed for hepatitis A virus (HAV) immunity and vaccinated if negative.
Recommendations for patients requiring hepatitis B virus and HIV treatment
In patients with HIV and HBV coinfection, HBV infection should be treated only in conjunction with HIV infection. Treatment of HBV infection alone without addressing the HIV infection will lead to emergence of HIV strains that are resistant to nucleoside reverse-transcriptase inhibitors (NRTI). 
Only tenofovir is fully active for the treatment of patients with known or suspected lamivudine-resistant HBV infection 
In treatment-naive patients with HIV/HBV coinfection, a regimen containing TDF plus FTC or TDF plus 3TC should be used as the backbone of HIV therapy.
If TDF cannot be used, entecavir may be used to treat HBV infection; however, owing to its weak activity against HIV,  this is not considered an active component of the antiretroviral regimen. Lamivudine-resistant strains of HBV may rapidly develop resistance; therefore, a higher dose (1 g/day) is recommended with more frequent HBV viral load monitoring.
If the HIV therapy requires modification (eg, due to HIV virologic failure), the HBV-active antiretroviral must be continued and new antiretrovirals added to achieve HIV viral suppression.
Treatment of Hepatitis C Virus With Coexisting HIV Infection
Increased rates of cirrhosis in patients with hepatitis C virus (HCV) are attributable to various factors, including older age, alcoholism, male sex, and HIV infection; higher rates of progression to cirrhosis are seen in patients with HCV/HIV.
HCV infection in patients with HIV infection can have significant consequences, including liver disease progression, cirrhosis, increased rates of end-stage liver disease, and shortened lifespan after hepatic decompensation. [6, 17]
Initial evaluation and treatment recommendations for patients with hepatitis C virus/HIV coinfections
Prior to initiating antiretroviral therapy, screen patients with HIV infection for HCV using sensitive immunoassays licensed for the detection of antibody to HCV in blood; to confirm the presence of chronic infection, persons who are HCV seropositive should be tested for HCV ribonucleic acid (RNA) using a qualitative or quantitative assay. 
Advise patients with HCV/HIV to avoid alcohol and receive HAV and HBV vaccines, if screened negative via serology.
Drug-induced liver injury (DILI) following antiretroviral therapy is more common in HIV/HCV coinfection; eradication of HCV infection may decrease the likelihood of antiretrovirus-associated DILI. 
It is important to monitor alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels at 1 month and then every 3 months after the initiation of antiretroviral therapy.
Antiretroviral therapy should be started in persons co-infected with HCV and HIV in accordance with the recommendations for initiating antiretroviral therapy in treatment-naive patients